Skip to main content

Table 1 (abstract P43). Patient-reported outcomes at Month 3 in patients with chronic migraine by baseline medication overuse status

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

 

Medication overuse

Without medication overuse

Placebo (N=113)

Erenumab 70 mg (N=77)

Erenumab 140 mg (N=78)

Placebo (N=168)

Erenumab 70 mg (N=111)

Erenumab 140 mg (N=109)

HIT-6 total score (range: 36–78)

 Baseline score, mean (SD)

63.8 (5.0)

63.9 (4.4)

63.3 (4.8)

63.0 (5.3)

63.0 (5.4)

62.2 (6.2)

 Change from baseline

−2.9 (−4.1, −1.7)

−5.2 (−6.7, −3.7)

−5.4 (−6.9, −3.9)

−3.4 (−4.4, −2.3)

−6.0 (−7.2, −4.6)

−5.8 (−7.1, −4.6)

 Difference from placebo

 

−2.3 (−4.2, −0.3)

−2.5 (−4.4, −0.6)

 

−2.6 (−4.2, −1.0)

−2.5 (−4.1, −0.8)

MIDAS total score

 Baseline score, mean (SD)

71.6 (52.7)

69.3 (43.4)

66.6 (55.7)

65.5 (58.2)

63.3 (47.5)

56.8 (49.4)

 Change from baseline

−3.6 (−12.0, 4.8)

−22.0 (−32.0, −12.1)

−16.1 (−26.1, −6.1)

−11.2 (−17.0, −5.5)

−18.40 (−25.2, 11.6)

−23.5 (−30.3, −16.6)

 Difference from placebo

 

−18.5 (−31.4, −5.5)

−12.5 (−25.4, 0.4)

 

−7.2 (−16.1, 1.7)

−12.2 (−21.1, −3.3)

MSQ-RFR (range: 0–100)

 Baseline score, mean (SD)

41.3 (17.4)

42.9 (16.5)

43.7 (17.3)

43.8 (17.7)

46.0 (19.4)

46.8 (20.3)

 Change from baseline

11.7 (8.0, 15.4)

17.1 (12.6, 21.5)

17.4 (13.0, 21.9)

12.0 (9.0, 15.1)

18.4 (14.7, 22.1)

20.6 (16.8, 24.3)

 Difference from placebo

 

5.4 (−0.4, 11.2)

5.7 (0.0, 11.51)

 

6.4 (1.6, 11.2)

8.5 (3.7, 13.3)

MSQ-RFP (range: 0–100)

 Baseline score, mean (SD)

60.8 (19.5)

63.8 (21.6)

61.1 (20.0)

59.9 (20.4)

60.6 (21.6)

64.2 (21.8)

 Change from baseline

7.7 (4.4, 11.1)

11.6 (7.6, 15.6)

10.5 (6.5, 14.4)

10.0 (7.3, 12.7)

14.2 (11.0, 17.5)

16.7 (13.4, 20.0)

 Difference from placebo

 

3.9 (−1.3, 9.0)

2.7 (−2.4, 7.9)

 

4.3 (0.0, 8.5)

6.8 (2.5, 11.0)

MSQ-EF (range: 0–100)

 Baseline score, mean (SD)

53.8 (24.3)

50.8 (23.9)

55.4 (24.8)

52.4 (26.7)

55.6 (26.1)

57.7 (27.9)

 Change from baseline

8.2 (4.2, 12.2)

17.1 (12.3, 21.9)

15.9 (11.1, 20.7)

11.3 (7.9, 14.8)

19.4 (15.3, 23.5)

21.2 (17.1, 25.4)

 Difference from placebo

 

8.9 (2.7, 15.1)

7.7 (1.5, 13.9)

 

8.1 (2.7, 13.4)

9.9 (4.5, 15.3)

  1. Data represent LS mean (95% CI) unless otherwise indicated.
  2. CI confidence interval, HIT-6 Headache Impact Test (higher score indicates worse outcome), LS least squares, MIDAS Migraine Disability Assessment (higher score indicates worse outcome), MSQ Migraine-Specific Quality-of-Life Questionnaire (higher score indicates better outcome), MSQ-EF Migraine-Specific Quality-of-Life Questionnaire emotional functioning, MSQ-RFP Migraine-Specific Quality-of-Life Questionnaire role function-preventive, MSQ-RFR Migraine-Specific Quality-of-Life Questionnaire role function-restrictive, N number of patients in the analysis set, SD standard deviation
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us